Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study-Reference-Cited by-同舟云学术

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study

Published:2012-08 Issue:2 Volume:77 Page:339-345
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Wu Yi-Long,Kim Joo-Hang,Park Keunchil,Zaatar Adel,Klingelschmitt Gaëlle,Ng Christina

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Chemotherapeutic management of stage IV non-small cell lung cancer;Socinski;Chest,2003

2. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer;Park;J Clin Oncol,2007

3. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer;Fidias;J Clin Oncol,2008

4. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind phase 3 study;Ciuleanu;Lancet,2009

5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials;Medicine;2024-06-07

2. Clinical outcomes of chemotherapy in cancer patients with different ethnicities;Cancer Reports;2023-05-07

3. MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells;Cell Communication and Signaling;2022-03-09

4. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis;PLOS ONE;2020-07-14

5. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS;Annals of Oncology;2019-02